Abstract
The CAPRISA 004 study in South Africa has accelerated the development of vaginal and rectal microbicides containing antiretrovirals that target specific enzymes in the reproduction cycle of HIV, especially reverse transcriptase inhibitors (RTI). In this review we discuss the potential relevance of HIV-1 RTIs as microbicides, focusing in the nucleotide RTI tenofovir and six classes of nonnucleoside RTIs (including dapivirine, UC781, urea and thiourea PETTs, DABOs and a pyrimidinedione). Although tenofovir and dapivirine appear to be most advanced in clinical trials as potential microbicides, several issues remain unresolved, e.g., the importance of nonhuman primates as a “gatekeeper” for clinical trials, the emergence and spread of drug-resistant mutants, the combination of microbicides that target different phases of viral reproduction and the accessibility to microbicides in low-income countries. Thus, here we discuss the latest research on RTI as microbicides in the light of the continuing spread of the HIV pandemic from the point of view of medicinal chemistry, virological, and pharmaceutical studies.
Keywords: Microbicide, HIV, reverse transcriptase, NtRTI, NNRTI, NRTI, gel, intravaginal ring, Anti-Retroviral, infection
Current HIV Research
Title: Reverse Transcriptase Inhibitors as Microbicides
Volume: 10 Issue: 1
Author(s): Paul Lewi, Jan Heeres, Kevin Arien, Muthusamy Venkatraj, Jurgen Joossens, Pieter Van der Veken, Koen Augustyns and Guido Vanham
Affiliation:
Keywords: Microbicide, HIV, reverse transcriptase, NtRTI, NNRTI, NRTI, gel, intravaginal ring, Anti-Retroviral, infection
Abstract: The CAPRISA 004 study in South Africa has accelerated the development of vaginal and rectal microbicides containing antiretrovirals that target specific enzymes in the reproduction cycle of HIV, especially reverse transcriptase inhibitors (RTI). In this review we discuss the potential relevance of HIV-1 RTIs as microbicides, focusing in the nucleotide RTI tenofovir and six classes of nonnucleoside RTIs (including dapivirine, UC781, urea and thiourea PETTs, DABOs and a pyrimidinedione). Although tenofovir and dapivirine appear to be most advanced in clinical trials as potential microbicides, several issues remain unresolved, e.g., the importance of nonhuman primates as a “gatekeeper” for clinical trials, the emergence and spread of drug-resistant mutants, the combination of microbicides that target different phases of viral reproduction and the accessibility to microbicides in low-income countries. Thus, here we discuss the latest research on RTI as microbicides in the light of the continuing spread of the HIV pandemic from the point of view of medicinal chemistry, virological, and pharmaceutical studies.
Export Options
About this article
Cite this article as:
Lewi Paul, Heeres Jan, Arien Kevin, Venkatraj Muthusamy, Joossens Jurgen, Van der Veken Pieter, Augustyns Koen and Vanham Guido, Reverse Transcriptase Inhibitors as Microbicides, Current HIV Research 2012; 10 (1) . https://dx.doi.org/10.2174/157016212799304643
DOI https://dx.doi.org/10.2174/157016212799304643 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot topic: Targets of Research in the Metabolic Syndrome (Guest Editor: Lindsay Brown)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Inflammatory Mechanisms of Glucocorticoids Targeting Granulocytes
Current Drug Targets - Inflammation & Allergy Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Editorial [Hot Topic:Drug Targets in Ageing and Age-Associated Diseases (Executive Editors: C. Caruso and E. Jirillo)]
Current Pharmaceutical Design Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Collagen-Binding Integrins as Pharmaceutical Targets
Current Pharmaceutical Design Corticosteroids for the Inflammatory Response to Cardiopulmonary Bypass: An Update
Current Pharmaceutical Design Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Renal Innervation in Resistant Hypertension: A Review of Pathophysiology and Renal Denervation as Potential Treatment
Current Hypertension Reviews Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapy Against Reperfusion-induced Microvascular Injury
Current Pharmaceutical Design Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes
Current Pharmaceutical Design The Versatile Stress Protein Mortalin as a Chaperone Therapeutic Agent
Protein & Peptide Letters